• 1
    Vail DM, Thamm DH. Hematopoietic tumors. In: EttingerSJ, FeldmanEC, eds. Textbook of Veterinary Internal Medicine, 6th ed. St Louis, MPO: Elsevier Saunders; 2005:732747.
  • 2
    Vail DM, Kisseberth WC, Obradovich JE, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleorlar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp Hematol 1996;24:807815.
  • 3
    Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs: A morphologic, immunologic and clinical study. Cancer 1990;66:480490.
  • 4
    Ruslander DA, Gebhard DH, Tompkins MB, et al. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 1997;11:169172.
  • 5
    Fournel-Fleury C, Magnol JP, Bricaire P, et al. Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human non-Hodgkin's lymphomas. J Comp Pathol 1997;117:3559.
  • 6
    Appelbaum FR, Sale GE, Storb R, et al. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy. Hematol Oncol 1984;2:151168.
  • 7
    Teske E, Van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:17221728.
  • 8
    Fournel-Fleury C, Ponce F, Felman P, et al. Canine T-cell lymphomas: A morphological, immunological and clinical study of 46 new cases. Vet Pathol 2002;39:92109.
  • 9
    Wilkerson MJ, Dolce K, Koopman T, el al. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD Molecules. Vet Immunol Immunopathol 2005;106:179196.
  • 10
    Culmsee K, Simon D, Mischke R, et al. Possibilities of flow cytometeric analysis for immunophenotypic characterization of canine lymphoma. J Vet Med A Physiol Pathol Clin Med 2001;49:99204.
  • 11
    Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120124.
  • 12
    Williams LE, Johnson JL, Hauck ML, et al. Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703709.
  • 13
    Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. J Vet Intern Med 1991;5:268271.
  • 14
    Rosol TJ, Capen CC. Biology of disease: Mechanism of cancer-induced hypercalcemia. Lab Invest 1992;67:680702.
  • 15
    Weller RE, Theilen GH, Madewell BR. Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia. J Am Vet Med Assoc 1982;181:891893.
  • 16
    Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989–2000). J Vet Intern Med 2002;16:576580.
  • 17
    Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:12951306.
  • 18
    Gobbi PG, Cavalli C, Rossi A, et al. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients. Haematologica 1987;72:523528.
  • 19
    Hancock BW, Vaughan HG, Vaughan HB, et al. British National Lymphoma Investigation randomized study of MOPP (mustine, oncovin, procarbazine, prednisolone) against LOPP (leukeran substituted for mustine) in advance Hodgkin's disease—Long term results. Br J Cancer 1991;63:579582.
  • 20
    Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva 1980:2125.
  • 21
    Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:195213.
  • 22
    Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. In: WithrowSJ, VailDM, ed. Small Animal Clinical Oncology, 4th ed. St Louis, MO: Saunders Elsevier; 2007:699733.
  • 23
    Starrak GS, Berry CR, Page RL, et al. Correlation between thoracic radiographic changes and remission/survival duration in 270 dogs with lymphosarcoma. Vet Radiol Ultrasound 1997;38:411418.
  • 24
    Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704709.
  • 25
    Thomas R, Smith KC, Ostrander EA, et al. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridization and a panel of single locus probes. Brit J of Cancer 2003;89:15301537.
  • 26
    Goldie JH, Coldman AJ. The genetic origins of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 1984;44:36433653.
  • 27
    Tew KD, Colvin OM, Jones RB. Clinical and high-dose alkylating agents. In: ChabnerBA, LongoDL, eds. Cancer Chemotherapy and Biotherapy Principles and Practice, 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:283309.
  • 28
    Bergman PJ. Multidrug resistance. In: BonaguraJD, ed. Kirk's Current Veterinary Therapy XIII Small Animal Practice. Philadelphia, PPA: WB Saunders Company; 2000:479482.
  • 29
    Morrison-Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for treatment of canine lymphoma. Vet Compar Oncol 2003;1:180190.
  • 30
    Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and DTIC chemotherapy for the treatment of resistant lymphoma in dogs. J Vet Intern Med 2008;22:164171.
  • 31
    Kaufman DC, Chabner BA. Clinical strategies for cancer treatment: The role of drugs. In: ChabnerBA, LongoDL, eds. Cancer Chemotherapy and Biotherapy Principles and Practice, 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:114.
  • 32
    Valli VE. VDx Veterinary Pathology Services. Personal communication, August 2008.
  • 33
    Valli VE, Vernau W, De Lorimier LP, et al. Canine indolent nodular lymphoma. Vet Pathol 2006;43:241256.